Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.

ABSTRACT:

Purpose

Oncogenic mutations in KRAS have been identified in >85% of pancreatic ductal adenocarcinoma (PDAC) cases, with G12D, G12V, and G12R being the most frequent variants. Using large clinical and genomic databases, this study characterizes prognostic and molecular differences between KRAS variants, focusing on KRASG12D and KRASG12R.

Experimental design

PDAC samples were tested using DNA and RNA sequencing. The MAPK activation score and tumor microenvironment were analyzed from RNA expression data. Real-world overall survival (OS) obtained from insurance claims data was calculated from tissue collection to last contact. Significance was determined by χ2 and Fisher exact tests.

Results

A total of 3,755 patients with PDAC harboring KRASG12D (n = 1,766), KRASG12V (n =

SUBMITTER: Ardalan B 

PROVIDER: S-EPMC11911800 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature